<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="154855">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02095691</url>
  </required_header>
  <id_info>
    <org_study_id>RENABLATE-II</org_study_id>
    <nct_id>NCT02095691</nct_id>
  </id_info>
  <brief_title>RENABLATE-II Feasibility - 157</brief_title>
  <acronym>RENABLATE-II</acronym>
  <official_title>A Prospective, Multi-center, Non Randomized, Feasibility Study of Catheter Based Renal Denervation to Treat Resistant Hypertension (RENABLATE-II- 157)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biosense Webster, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biosense Webster, Inc.</source>
  <oversight_info>
    <authority>Czech Republic:  SUKL</authority>
    <authority>Belgium:  Agence Fédérale des médicaments et des produits de santé (AFMPS)</authority>
    <authority>Italy:  Agenzia Italiana del Farmaco (AIFA)</authority>
    <authority>Spain: Agencia Española de Medicamentos y Productos Sanitarios (AEMPS)</authority>
    <authority>New Zealand:  Health and Disability Ethics Committees (HDEC)</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The RENABLATE-II study is a prospective, multi-center, non-randomized feasibility study of
      Catheter-Based Renal Denervation to evaluate the safety and effectiveness of the
      investigational Celsius® ThermoCool® RD Multi-electrode Ablation Catheter and Celsius®
      ThermoCool® RDGW Multi-electrode Ablation Catheter and integrated ablation system to treat
      resistant hypertension.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">May 2017</completion_date>
  <primary_completion_date type="Anticipated">March 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Renal Denervation Safety</measure>
    <time_frame>3 years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Safety of Renal Denervation in patients with resistant hypertension as measured by Adverse Events [Time Frame: 1, 3, 6 months, annually up to 3 years]</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Freedom from adverse renal events through 6 months post-procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Reduction of average office based measurements of systolic blood pressure between baseline and 6 months post-procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Office Blood Pressure Change</measure>
    <time_frame>3 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in office Systolic (SBP) and Diastolic Blood Pressure (DBP) from baseline to 1, 3, 12 months post-procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Blood Pressure</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Incidence of subjects achieving target SBP (&lt;130 mmHg) at 6 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Pressure Changes</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Incidence of changes in medical regimen for high blood pressure and low blood pressure through 6 months post-procedure.
Incidence of subjects achieving a ≥ 10 mmHg reduction in Systolic Office BP at 1 month, 3 months, 6 months and 12 months post procedure</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Renal Denervation</condition>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Resistant Hypertension</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Renal Sympathetic Denervation</intervention_name>
    <description>Device: Celsius® ThermoCool® RD Multi-electrode Ablation Catheter, Celsius® ThermoCool® RDGW Multi-electrode Ablation Catheter</description>
    <arm_group_label>Resistant Hypertension</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Celsius® ThermoCool® RD Multi-electrode Ablation Catheter, Celsius® ThermoCool® RDGW Multi-electrode Ablation Catheter</intervention_name>
    <arm_group_label>Resistant Hypertension</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject has a systolic blood pressure ≥ 140 mmHg based on an average of 3 office
             blood pressure readings measured according to the BP guidelines.

          2. Subject is adhering to a stable drug regimen of at least 3 different classes of
             anti-hypertensive medications, including a diuretic (with no changes for a minimum of
             2 weeks prior to enrollment) at optimal dose and is expected to be maintained for at
             least 6 months.

          3. Subject is &gt; 18 and &lt; 85 years of age.

          4. Subject agrees to have all study procedures performed, and is competent and willing
             to provide written, informed consent to participate in this study.

        Key Exclusion Criteria:

          1. A secondary cause of hypertension, e.g. &quot;white coat&quot; hypertension (assessed by 24 h
             ABPM at  physician's discretion), primary aldosteronism, pheochromocytoma, renal
             artery stenosis, drug induced-hypertension, Adult Polycystic kidney Disease, renal
             cell carcinoma, pyelonephritis, glomerulonephritis,  coarctation of the aorta,
             acromegaly, Cushing's Syndrome, Conn's (primary hyperaldosteronism), polyarteritis
             nodosum, systemic sclerosis, parenchymal kidney disease, obstructive sleep apnoea
             based on a workup performed within the 12 months preceding enrollment.

          2. Subject has aorto-ilio-femoral artery anatomy not suitable for treatment with the
             investigational device(s).

          3. Subject has main renal arteries that are &lt; 20 mm in length or &lt; 4 mm in diameter.

          4. Subject has a prior history of any renal artery intervention including but not
             limited  to balloon angioplasty, stenting , renal denervation or  surgery.

          5. Subject has an estimated glomerular filtration rate (eGFR) of &lt; 45mL/min/1.73m2,
             using the MDRD formula.

          6. Subject has type 1 diabetes mellitus.

          7. Subject has history of Myocardial Infarction, unstable angina pectoris, or a
             cerebrovascular accident in the 6 months period prior to enrolment, or documented
             widespread atherosclerosis, intravascular thrombosis or unstable plaques.

          8. Subject has hemodynamically significant valvular heart disease for which reduction of
             blood pressure would be considered hazardous.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Liesbeth Vanderlinden</last_name>
    <email>lvanderl@its.jnj.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Na Homolce Hospital</name>
      <address>
        <city>Prague</city>
        <zip>15 030</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liz Coling</last_name>
      <phone>+420 257 271 111</phone>
    </contact>
    <investigator>
      <last_name>Petr Neuzil</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Charles University Hospital</name>
      <address>
        <city>Prague</city>
        <zip>12808</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martina Striteska, MD</last_name>
      <phone>+420 224 96 2605</phone>
    </contact>
    <investigator>
      <last_name>Jean-Claude Lubanda, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Generale Regionale</name>
      <address>
        <city>Bari</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mario Petruzzi, MD</last_name>
      <phone>+39 3474868620</phone>
    </contact>
    <investigator>
      <last_name>Massimo Grimaldi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mercy Angiography</name>
      <address>
        <city>Epsom</city>
        <state>Auckland</state>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barbara Joppa</last_name>
      <phone>+64 9630 1961</phone>
    </contact>
    <investigator>
      <last_name>John Ormiston, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Clinic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Manel Sabaté, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Czech Republic</country>
    <country>Italy</country>
    <country>New Zealand</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 24, 2014</lastchanged_date>
  <firstreceived_date>March 21, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
